2026-03-03 - IQV - IQVIA Holdings Deep Dive

Article published Mar 3, 2026. Prices below use latest available snapshots.

IQV Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium Status: Researching — RSI 17.4 (data as of 02/23), continued extreme; approaching Feb 12 capitulation low

Quick Snapshot

Signal	Reading
Overall	🔴 RSI 17.4 (last OHLC: 02/23) — sustained extreme oversold. Price $162.31, 7D improved slightly (-1.3% vs prior -8.4%), -32.2% in 30 days. SMA20 $195.64. No sustained recovery forming.
Moat	Wide
Key insight	IQV OHLC data last updated 02/23. The -1.3% 7D (vs prior -8.4%) shows the pace of decline may be slowing. RSI at 17.4 has been sustained for 3+ weeks now without recovery — the longest extreme RSI streak in our coverage. Price at $162.31 is approaching the Feb 12 capitulation intraday low ($156.67). If that breaks, $136 (April 2025 52wk low) is next. Key signal to watch: RSI stabilizing above 20 for 3+ consecutive days.

Action Matrix

Action	Level	Why
Current	🔍 Research / Watch	RSI stuck at extreme but no stabilization signal yet. Falling knife risk.
Entry Zone	$155 - $170	Current $162.31 — in zone, but downtrend may continue
Stop-Loss	$134 (-17%)	Below April 2025 52-week low ($135.97)
Target	$217 (+34%)	Return to 3-month mean; conservative vs $244 highs

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
IQV	$162.31	-2.0%	-1.3%	-32.2%	—	-32.7%	17↓	🔴 Extreme Oversold	🔍 Watch

Note: OHLC data last updated 2026-02-23. RSI 17.4, SMA20 $195.64.

Legend

RSI ↓ = Oversold (<30) — potential buying opportunity (but watch for continued deterioration)
52wkHi = -32.7% from $241.04 in-window peak
52wk Low = $135.97 (Apr 9, 2025)
SMA20 = $195.64 (price is -17.0% below SMA)

Price vs Last Deep Dive (02/26)

Metric	02/26	03/03	Change
Price	$162.31	$162.31	$0.00 (data stale since 02/23)
RSI	17.4	17.4	0.0 (stale)
SMA20	$195.64	$195.64	Unchanged (stale)
vs SMA	-17.0%	-17.0%	Stale

Update (03/03): IQV OHLC has not refreshed beyond 02/23. No recovery signal visible. The 7D reading (-1.3%) is better than the -8.4% 7D seen on 02/26, suggesting the pace of decline may be slowing — but with stale data it's hard to confirm. RSI 17.4 has been sustained for over 3 weeks. The critical test remains: does the $156.67 Feb 12 low hold?

Company Overview

One-Liner

IQVIA provides data analytics, technology solutions, and contract research services to the life sciences industry.

Business Model

Question	Answer
What they sell	Clinical trial management (CRO), healthcare data/analytics, technology platforms, commercial services
Who pays	Pharma companies (90% of top 25 are clients), biotech firms, medical device companies, government agencies
Revenue model	Long-term contracts (CRO), SaaS subscriptions (analytics), project-based (consulting)
How sticky	Very high — multi-year CRO contracts, deeply embedded analytics platforms, proprietary data moat

Key Segments

Segment	Revenue %	Growth	Notes
R&D Solutions (R&DS)	55%	+4.3% YoY	Clinical trial management — $8,896M in 2025
Technology & Analytics (TAS)	40%	+7.6% YoY	Cloud apps, real-world evidence, data analytics — $6,626M in 2025
Contract Sales & Medical (CSMS)	5%	Flat	Merging into TAS in 2026

Competitive Analysis

Competitive Moat

Moat Type	Present?	Evidence
Network effects	🟢	More data from trials = better analytics = attracts more clients
Switching costs	🟢	Multi-year contracts, deeply embedded platforms, proprietary data dependencies
Cost advantages	🟢	Scale across 100+ countries, largest CRO workforce globally
Intangible assets	🟢	Proprietary healthcare datasets covering 1B+ patient records, regulatory expertise
Efficient scale	🟢	$16.3B revenue vs ICON's $7.8B — economies of scale in trial management

Moat Width: Wide Moat Trend: Widening (AI + data flywheel)

Financials Summary

Metric	2025	2024	Trend
Revenue	$16,310M	~$15,480M	📈 +5.4%
Adj. EPS	$11.92	$11.13	📈
Net Debt/EBITDA	~3.4x	~3.5x	📈 Deleveraging

Valuation

Metric	Current	5Y Avg	Signal
P/E (trailing)	~14x	~50x	🟢 Near 5Y floor
P/E (forward)	~13x	~25x	🟢
EV/EBITDA	~10x	~15x	🟢

Fair Value Estimate: $210-$230 (based on 16-18x forward EPS of $12.70 midpoint guidance)

Bull Case

Why This Could Work

Extreme valuation compression — Trading at ~13x forward P/E vs 5Y avg ~25x. Near 5Y lows.
AI/agentic platform catalyst — Strategic AWS partnership, deploying agentic AI across clinical trials.
Irreplaceable data moat — 1B+ patient records, 33% health analytics share, 90% of top pharma are clients.
CRO market tailwinds — CRO market growing at 8.3% CAGR to $126B by 2030.
100% earnings beat rate — Every quarter for 4+ years.

Bear Case

What Could Go Wrong

Clinical trial cancellations accelerating — Biotech funding pullback leads to more cancellations.
Debt burden — ~$13B debt with $80M step-up in interest expense in 2026.
2026 EPS guidance below expectations — $12.55-$12.85 guidance disappointed consensus.
Competition from specialized AI analytics — New entrants with superior AI capabilities.

Thesis Killers

R&DS backlog declining for 3+ consecutive quarters
Major pharma client defecting to competitor
Debt covenant breach or downgrade to junk

Entry Strategy

Technical Levels

Level	Price	Notes
Support 1	$157	Feb 12 intraday low area — KEY level being tested
Support 2	$136	April 2025 52-week low — next stop if support fails
Resistance 1	$187	Feb 6 close (post-earnings)
Resistance 2	$195.64	SMA20
52-week high	$241.04	In-window high
52-week low	$135.97	Apr 9, 2025

Entry Approach

Strategy	Details
Entry trigger	RSI stabilizes above 20 for 3+ consecutive days
Starter position	1% of portfolio
Add on	Stabilization above $175 with RSI > 25
Full position at	Confirmation of Q1 2026 guidance being met

Research Log

Date	Update
2026-02-15	Created deep dive. RSI 14 extreme oversold. -31% 30D on guidance miss. Wide moat, 100% earnings beat rate, fair value $210-$230.
2026-02-22	Price refresh. Price $165.62 (-0.8% from 02/15). RSI improved from 14 to 25.5 — stabilization. 30D still -31.4%. SMA20 $199.29. Still in research/watch mode.
2026-02-26	Price deteriorated. $162.31 (-2.0% from 02/22). RSI slipped from 25.5 → 17.4 (reversal of recovery). -8.4% in 7 days, -32.2% in 30 days. No stabilization forming. Approaching Feb 12 low ($156.67). Status: Research/Watch.
2026-03-03	OHLC stale (last entry 02/23). Data shows same $162.31, RSI 17.4. 7D improved to -1.3% (vs prior -8.4%) — possible slowing of decline. RSI at 17.4 for 3+ weeks is the longest extreme streak in our coverage. No entry signal yet.

The Gold

Key Discoveries

Discovery	Implication
RSI 14 → 25 → 17 (failed recovery)	Sustained institutional selling; no bottom formed yet
3+ weeks at extreme RSI (14-17)	Unprecedented in our coverage — unusual institutional pressure
100% earnings beat rate vs current 13x fwd P/E	If guidance was conservative, significant re-rating upside
7D declining from -8.4% → -1.3%	Possible deceleration in selling — early signal worth watching

Open Questions

Has the Feb 12 low ($156.67) held, or has IQV broken down further?
Is the Q4 cancellation trend in R&DS worsening or stabilizing?
What is the AI platform revenue contribution timeline?
Is the $13B debt a concern given rising refinancing costs?
Current price and RSI unknown

Mistakes (If Applicable)

Mistake	Lesson
N/A — not entered yet	RSI 25.5 "recovery" on 02/22 was a head fake — shows importance of sustained stabilization

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.